Drug Profile
SL 1111
Latest Information Update: 25 Jun 2001
Price :
$50
*
At a glance
- Originator Selectus Pharmaceuticals [CEASED]
- Class Antiglaucomas
- Mechanism of Action Beta-adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 25 Jun 2001 Discontinued-Preclinical for Glaucoma in USA (Ophthalmic)
- 05 Mar 1998 New profile
- 05 Mar 1998 Preclinical development for Glaucoma in USA (Ophthalmic)